Skip to content
10-Q

Quarterly Report

Neuphoria Therapeutics Inc. NEUP

0000950170-25-020473

← back to feed
Filed
Feb 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Feb 12, 2025 1.76M sh
Current Liabilities Q2 2025 · Dec 31, 2024 $2.13M
Current Liabilities Q2 2025 · Jun 30, 2024 $3.83M
Total Liabilities Q2 2025 · Dec 31, 2024 $4.42M
Total Liabilities Q2 2025 · Jun 30, 2024 $10.16M
Current Assets Q2 2025 · Dec 31, 2024 $4.4M
Current Assets Q2 2025 · Jun 30, 2024 $13.19M
Total Assets Q2 2025 · Dec 31, 2024 $18.17M
Total Assets Q2 2025 · Jun 30, 2024 $27.65M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $12.61M
Cash And Equivalents Q2 2025 · Dec 31, 2023 $10.15M
Net Income Q2 2025 · Jun 30, 2024 −$15.5M
Net Income Q2 2025 · Dec 31, 2023 −$4.55M
Net Income Q2 2025 · Dec 31, 2023 −$10.03M
Net Income Q2 2025 · Sep 30, 2023 −$5.47M
Shares Diluted Q2 2025 · Dec 31, 2023 857.26K sh
Shares Diluted Q2 2025 · Dec 31, 2023 773.98K sh
Operating Cash Flow Q2 2025 · Dec 31, 2023 −$8.37M
Stockholders Equity Q2 2025 · Dec 31, 2023 $19.5M
Stockholders Equity Q2 2025 · Sep 30, 2023 $17.23M
Stockholders Equity Q2 2025 · Jun 30, 2023 $22.01M
Eps Diluted Q2 2025 · Dec 31, 2023 −$5.31
Eps Diluted Q2 2025 · Dec 31, 2023 −$12.96
Eps Basic Q2 2025 · Dec 31, 2023 −$5.31
Eps Basic Q2 2025 · Dec 31, 2023 −$12.96
Sga Expense Q2 2025 · Dec 31, 2023 $2.52M
Sga Expense Q2 2025 · Dec 31, 2023 $4.9M
Rd Expense Q2 2025 · Dec 31, 2023 $2.03M
Rd Expense Q2 2025 · Dec 31, 2023 $5.12M
Operating Income Q2 2025 · Dec 31, 2023 −$4.55M
Operating Income Q2 2025 · Dec 31, 2023 −$10.02M